Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Will, Howe"'
Publikováno v:
MSMR. 29(7)
Autor:
Will Howe
Publikováno v:
BMJ. :o2698
Autor:
Will Howe, James G. Gardner, Dennis W. Buckman, Amy DeGroff, Janet Royalty, Theodore H. Poister, Nikki S. Hayes
Publikováno v:
Cancer. 120:2566-2574
BACKGROUND: Little empirical evidence exists about the effectiveness of performance management systems in government. This study assessed the effectiveness of the performance management system of the National Breast and Cervical Cancer Early Detectio
Autor:
Kathleen A. Cronin, Donna R. Rivera, Wendy S. Rubinstein, Mary E. Charlton, Linda Coyle, Robert S. Miller, George Anthony Komatsoulis, Nicola Schussler, Will Howe, Lynne Penberthy, Charles F. Lynch, Andrej Kolacevski, Serban Negoita
Publikováno v:
Journal of Clinical Oncology. 37:e18317-e18317
e18317 Background: The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program curates population-based cancer data representing 34% of the US population. CancerLinQ is an ASCO initiative that collects and analyzes
Autor:
Rosemary D. Cress, Nicola Schussler, Kathleen A. Cronin, Lloyd Mueller, Valentina I. Petkov, Dennis Deapen, Charles L. Wiggins, Xiao-Cheng Wu, Antoinette M. Stroup, Steven Shak, Nadia Howlader, Charles F. Lynch, Carol Sweeney, Kevin C. Ward, Lynne Penberthy, Dave P. Miller, Will Howe, Stephen M. Schwartz, Ann G. Schwartz, Frederick L. Baehner, Brenda Y. Hernandez, Sally L. Glaser, Thomas C. Tucker, Nathan Gliner
Publikováno v:
NPJ breast cancer, vol 2, iss 1
NPJ Breast Cancer
NPJ Breast Cancer
The 21-gene Recurrence Score assay is validated to predict recurrence risk and chemotherapy benefit in hormone-receptor-positive (HR+) invasive breast cancer. To determine prospective breast-cancer-specific mortality (BCSM) outcomes by baseline Recur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbb3f7d82bdf6e55f5da66671e90da24
https://escholarship.org/uc/item/6td7q3bv
https://escholarship.org/uc/item/6td7q3bv
Autor:
Frederick L. Baehner, Stephen M. Schwartz, Steven Shak, Brenda Y. Hernandez, Xiao-Cheng Wu, Valentina I. Petkov, Rosemary D. Cress, Lloyd Mueller, Will Howe, Antoinette M. Stroup, Kevin C. Ward, Nathan Gliner, Dennis Deapen, Carol Sweeney, Thomas C. Tucker, Kathleen A. Cronin, Nadia Howlader, Charles F. Lynch, Dave P. Miller, Ann G. Schwartz, Sally L. Glaser, Nicola Schussler, Charles L. Wiggins, Lynne Penberthy
Publikováno v:
npj Breast Cancer, Vol 4, Iss 1, Pp 1-1 (2018)
In the original version of the published article, line three of the third paragraph of the methods stated “Excluding patients with micrometastatic disease, the 5-year BCSM for patients with Recurrence Score results n = 2,617) was 1.3% (95% CI, 0.6
Autor:
Amy, DeGroff, Janet E, Royalty, Will, Howe, Dennis W, Buckman, James, Gardner, Theodore, Poister, Nikki, Hayes
Publikováno v:
Cancer
BACKGROUND: Little empirical evidence exists about the effectiveness of performance management systems in government. This study assessed the effectiveness of the performance management system of the National Breast and Cervical Cancer Early Detectio
Autor:
Allison W. Kurian, Kathleen A. Cronin, Will Howe, Valentina I. Petkov, Nadia Howlader, Nicola Schussler, Lynne Penberthy
Publikováno v:
Journal of Clinical Oncology. 34:6553-6553
6553Background: The 21-gene assay has been used in clinical practice since 2004 to predict the recurrence and chemotherapy benefit of breast cancer in patients with hormone receptor positive (HR+) ...
Autor:
Nadia Howlader, Nathan Gliner, Valentina I. Petkov, Kathleen A. Cronin, Steven Shak, Dave P. Miller, Frederick L. Baehner, Lynne Penberthy, Nicola Schussler, Will Howe
Publikováno v:
Journal of Clinical Oncology. 34:574-574
574Background: BC diagnoses in older patients (pts) are rising as population demographics change and life expectancy increases. The TEAM study (N = 9,766) reported worse outcomes for older pts with...
Autor:
Lynne Penberthy, Kathleen A. Cronin, Nadia Howlader, Steven Shak, Nathan Gliner, Valentina I. Petkov, Nicola Schussler, Dave P. Miller, Frederick L. Baehner, Will Howe
Publikováno v:
Journal of Clinical Oncology. 34:176-176
176 Background: NCI’s SEER Program provides cancer incidence and survival statistics for ~28% of the US. New research models are needed to characterize the use and impact of genomic tests on patient outcomes. Genomic Health and SEER collaborated to